Arvinas (ARVN) Other Non-Current Liabilities (2017 - 2018)
Arvinas' (ARVN) quarterly Other Non-Current Liabilities came in at $150000.0 in Q4 2018, up 194.76% year-on-year from $50888.0 in Q4 2017, and up 194.76% quarter-over-quarter from $50888.0 in Q4 2017.
Arvinas (ARVN) Other Non-Current Liabilities (2017 - 2018) Analysis & Trends
Arvinas' Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $150000.0 for Q4 2018.
- On a quarterly basis, Other Non-Current Liabilities rose 194.76% year-over-year to $150000.0 in Q4 2018; TTM through Dec 2018 was $150000.0, a 194.76% increase from a year earlier, with the FY2018 full-year figure at $150000.0, up 194.76% from the prior year.
- Other Non-Current Liabilities climbed to $150000.0 in Q4 2018 per ARVN's latest filing, from $50888.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $150000.0 in Q4 2018 and bottomed at $50888.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Arvinas | 512.64 Mn | -102.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 150,000.00 |
| Dec 31, 2017 | 50,888.00 |